tiprankstipranks
Analyst Profile
Followed by 599 other investors
.
Ed Arce

Ed Arce

H.C. Wainwright
Wall Street Analyst
Ranked #1,193 out of 8,047 Analysts on TipRanks (#2,062 out of 21,521 overall experts)

Success Rate

40%
155 out of 388 Profitable Transactions

Average Return

8.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Ed Arce's ratings since 2012 and opened each position for the duration of 1 Year:
39.95% of your transactions would have been profitable with an average return of 8.3%

Stock Rating Distribution

1KRatings
82.87% Buy
16.87% Hold
0.26% Sell
Distribution of Ed Arce's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market
United KingdomUK Market

Best Rating

Stock:
Arcturus Therapeutics
(ARCT)
Rating Type:Buy
Dates:Dec 13, 2019 - Dec 13, 2020
Gain:800.00%
The most profitable rating made by Ed Arce

Ed Arce's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Ardea Biosciences
Hold
Assigned
0.00%
1
Affymax
Sell
Downgraded
$0.50
(6844.44% Upside)
0.00%
2
NPS Pharma
Buy
Reiterated
0.00%
1
Durata
Hold
Downgraded
0.00%
7
Xoma
Buy
Reiterated
$9.00
(-55.18% Downside)
0.00%
3
Acura Pharmaceuticals
Buy
Reiterated
$5.00
(7042.86% Upside)
0.00%
8
BioCryst
Buy
Reiterated
$20.00
(36.61% Upside)
0.00%
12
Neptune Wellness Solutions
Buy
Reiterated
$5.00
(214.47% Upside)
0.00%
1
Sucampo Pharmaceuticals
Buy
Initiated
0.00%
12
Relypsa Inc
Hold
Downgraded
0.00%
6
List of latest recommendations made by Ed Arce. Click to expand and see Ed Arce's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More